Table 1: Final meta analysis.
|
Identifying
data |
Population
characteristics |
MRI |
Standard
biopsy |
Targeted
biopsy |
|||||||||
|
Source |
Year |
Population size |
Age |
PSA
(ng/mL) |
Prior biopsy |
MRI Series |
Field strength (T) |
Pelvic array coil/ endorectal coil
(y/n) |
Grading score |
Biopsy type |
Cores taken per patient |
MRI targeted biopsy |
Targeted cores per lesion (avg) |
|
Da Rosa, et al. |
2014 |
72 |
Mean 64.8 |
Mean 5.0 |
100% on active surveillance |
T2, DWI, DCE |
3 |
y/n |
5-point scale |
TRUS |
12 |
MRI computer fusion (Uronav) |
2 |
|
Fiard, et al. |
2013 |
30 |
Mean 64 |
Mean 6.3 |
Mixed - 43% biopsy naïve, 57% previous negative |
T2, DWI, DCE |
3 |
n/n |
PI-RADS |
TRUS |
12 |
MRI computer fusion (Urostation) |
2 |
|
Haffner, et al. |
2010 |
555 |
Mean 64 |
Median 6.75 |
100% biopsy naïve |
T2, DCE |
1.5 |
y/n |
5-point scale |
TRUS |
10-12 |
MRI cognitive fusion |
2 |
|
Hu, et al. |
2014 |
90 |
Median 63 |
Median 4.2 |
100% on active surveillance |
T2, DWI, DCE |
3 |
y/n |
5-point scale |
TRUS |
12 |
MRI computer fusion (Artemis) |
2 |
|
Kasivisvanathan, et al. |
2013 |
182 |
Mean 63.3 |
Median 6.7 |
Mixed - 43% biopsy naïve, 18% previous negative, 39% on
active surveillance |
T2, DWI, DCE |
1.5 and 3 |
y/n |
5-point scale |
Transperineal |
20 |
MRI cognitive fusion |
NR |
|
Lawrence, et al. |
2014 |
39 |
Mean 64 |
Median 10.0 |
100% previous negative |
T2, DWI |
1.5 or 3 |
y/n |
PI-RADS |
Transperineal |
24-36 |
MRI computer fusion (Biopsee) |
3 |
|
Mozer, et al. |
2014 |
152 |
Mean63 |
Mean 6.0 |
100% biopsy naïve |
T2, DWI, DCE |
1.5 |
y/n |
5-point scale |
TRUS |
12 |
MRI computer fusion (Urostation) |
2 |
|
*Park, et al. |
2011 |
44 |
Mean 63 |
Mean 6.1 |
100% biopsy naïve |
T2, DWI, DCE |
3 |
NR |
Low, moderate, high |
TRUS |
10-12 |
MRI cognitive fusion |
NR |
|
Pepe et al. |
2013 |
78 |
Median 63 |
Median 11.0 |
100% previous negative |
T2, DWI, DCE, MRSI |
3 |
y/n |
Low, moderate, high |
TRUS |
15 |
MRI cognitive fusion |
3.5 |
|
Pokorny, et al. |
2014 |
223 |
Median 63 |
Median 5.3 |
100% biopsy naïve |
T2, DWI, DCE, MRSI |
3 |
y/n |
PI-RADS |
TRUS |
NR |
MRI In-bore |
2.5 |
|
Puech, et al. |
2013 |
95 |
Median 65 |
Mean 10.05 |
Mixed - 68% biopsy naïve, 32% previous negative |
T2, DWI, DCE |
1.5 |
y/n |
5-point scale |
TRUS |
12 |
MRI cognitive fusion and MRI computer fusion (MyLab
Navigator) |
4 |
|
Quentin et al. |
2014 |
128 |
Mean 66.1 |
Mean 8.7, Median 6.7 |
100% biopsy naïve |
T2, DWI, DCE |
3 |
y/n |
PI-RADS |
TRUS |
12 |
MRI In-bore |
2 |
|
Radtke et al. |
2014 |
196 |
Median 64 |
Mean 7.3 |
Mixed - 61% biopsy naïve, 39% previous negative |
T2, DWI, DCE |
3 |
y/n |
PI-RADS |
Transperineal |
24 |
MRI computer fusion (Biopsee) |
2 |
|
Salami, et al. |
2014 |
140 |
Median 65 |
Median 8.0 |
100% previous negative |
T2, DWI, DCE |
3 |
y/y |
5-point scale |
TRUS |
12 |
MRI computer fusion (Uronav) |
2 |
|
Shakir, et al. |
2014 |
1,003 |
Median 62 |
Median 6.7 |
Mixed - 20% biopsy naïve, 80% previous negative |
T2, DWI, DCE, MRSI |
3 |
y/y |
Low, moderate, high |
TRUS |
12 |
MRI computer fusion (Uronav) |
2 |
|
Somford, et al. |
2013 |
54 |
Median 65 |
Mean 6.2 |
100% on active surveillance |
T2, DWI, DCE |
3 |
y/y |
Low, moderate, high |
TRUS |
9-12 |
MRI In-bore |
2 |
|
Sonn, et al. |
2013 |
94 |
Median 65 |
Median 7.5 |
100% previous negative |
T2, DWI, DCE |
3 |
y/n |
5-point scale |
TRUS |
12 (5 with saturation) |
MRI computer fusion (Artemis) |
4.2 |
|
Wysock, et al. |
2014 |
67 |
Mean 65 |
Mean 5.1 |
100% biopsy naïve |
T2, DWI, DCE |
3 |
y/n |
PI-RADS, 5-point scale |
TRUS |
12 |
MRI cognitive fusion and MRI computer fusion (Artemis) |
4 |
*MRI Group only.